Non-squamous Non-small Cell Lung Cancer Clinical Trials

18 recruitingLast updated: June 17, 2026

There are 18 actively recruiting non-squamous non-small cell lung cancer clinical trials across 45 countries. Studies span Phase 2, Phase 3, Phase 1. Top locations include Seoul, South Korea, Kaohsiung City, Taiwan, Madrid, Spain. Updated daily from ClinicalTrials.gov.


Non-squamous Non-small Cell Lung Cancer Trials at a Glance

18 actively recruiting trials for non-squamous non-small cell lung cancer are listed on ClinicalTrialsFinder across 6 cities in 45 countries. The largest study group is Phase 2 with 10 trials, with the heaviest enrollment activity in Seoul, Kaohsiung City, and Madrid. Lead sponsors running non-squamous non-small cell lung cancer studies include AstraZeneca, CatalYm GmbH, and Sichuan Baili Pharmaceutical Co., Ltd..

Browse non-squamous non-small cell lung cancer trials by phase

Treatments under study

About Non-squamous Non-small Cell Lung Cancer Clinical Trials

Looking for clinical trials for Non-squamous Non-small Cell Lung Cancer? There are currently 12 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Non-squamous Non-small Cell Lung Cancer trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Non-squamous Non-small Cell Lung Cancer clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 118 of 18 trials

Recruiting
Phase 2

Trial Investigating Visugromab and Nivolumab With or Without Docetaxel in 2L Treatment of Participants With Metastatic NSCLC

Metastatic Non-Squamous Non-Small Cell Lung CancerAdult Solid Tumor
CatalYm GmbH131 enrolled25 locationsNCT07246863
Recruiting
Phase 2Phase 3

A Study to Assess Adverse Events, Change in Disease Activity of Intravenous Telisotuzumab Adizutecan in Combination With Osimertinib as First-Line Treatment in Adult Participants With Locally Advanced Unresectable or Metastatic EGFR-Mutated Non-Squamous Non-Small Cell Lung Cancer

Non-squamous Non-small Cell Lung Cancer
AbbVie854 enrolled53 locationsNCT07005102
Recruiting
Phase 2

Efficacy & Safety of Olvimulogene Nanivacirepvec & Platinum-doublet + Physician's Choice of Immune Checkpoint Inhibitor Compared to Docetaxel in NSCL Cancer

Non-small Cell Lung CancerMetastatic Squamous Non-Small Cell Lung CarcinomaNon-Small Cell Lung Cancer (Stage III)+5 more
Genelux Corporation142 enrolled15 locationsNCT06463665
Recruiting
Phase 3

A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Metastatic Non-squamous NSCLC

Non-squamous Non-small Cell Lung Cancer
AstraZeneca878 enrolled283 locationsNCT06627647
Recruiting

RACE-2L: Real-World Assessment of Clinical Practice and Outcomes in Non-squamous NSCLC After Failure of Platinum-based Chemotherapy in Brazil

Non-squamous Non-small Cell Lung Cancer
AstraZeneca250 enrolled11 locationsNCT06491862
Recruiting
Phase 2

Phase II Clinical Study of JS207 (PD-1/VEGF Bispecific Antibody) Combination Therapies in Patients With Driver Gene-Positive, Advanced Non-Small Cell Lung Cancer After Failure of TKI Therapy

Non-squamous Non-small Cell Lung Cancer
Shanghai Junshi Bioscience Co., Ltd.78 enrolled1 locationNCT06868836
Recruiting
Phase 2

Trial Investigating Visugromab in Combination With Immunochemotherapy in 1L Treatment of Participants With Metastatic NSCLC

Metastatic Non-Squamous Non-Small Cell Lung CancerAdult Solid Tumor
CatalYm GmbH107 enrolled37 locationsNCT07098988
Recruiting
Phase 3

A Study to Compare Pharmacokinetics, Efficacy, Safety, and Immunogenicity of MB12 (Proposed Pembrolizumab Biosimilar) to Keytruda® in Non-small Cell Lung Cancer (BENITO Study)

Non-squamous Non-small Cell Lung Cancer
mAbxience Research S.L.726 enrolled151 locationsNCT06687369
Recruiting
Phase 3

Pharmacokinetic Similarity Between ABP 234 and Keytruda® (Pembrolizumab)

Early-stage Non-squamous Non-small Cell Lung Cancer (NSCLC)
Amgen154 enrolled128 locationsNCT06430866
Recruiting
Phase 2

A Study of BL-M07D1 in Combination With Pembrolizumab in Patients With Unresectable Locally Advanced or Metastatic HER2-Overexpressing Non-Squamous NSCLC

Non-squamous Non-small Cell Lung Cancer
Sichuan Baili Pharmaceutical Co., Ltd.80 enrolled1 locationNCT07264816
Recruiting
Phase 3

A Study of BL-M07D1 vs Pembrolizumab-platinum Chemotherapy in First-line Treatment of HER2-mutant Advanced or Metastatic Non-squamous NSCLC

Non-squamous Non-small Cell Lung Cancer
Sichuan Baili Pharmaceutical Co., Ltd.440 enrolled1 locationNCT07178795
Recruiting
Phase 2

IBI363 Combined With Chemotherapy or Pembrolizumab Combined With Chemotherapy as Neoadjuvant Therapy in Resectable Stage IB-III Non-Squamous Non-Small Cell Lung Cancer

Resectable Stage IB-III Non-Squamous Non-Small Cell Lung Cancer
Innovent Biologics (Suzhou) Co. Ltd.170 enrolled1 locationNCT07122687
Recruiting
Phase 2Phase 3

A Study of HS-20117 Combined With Aumolertinib in Participants With Advanced Non-Squamous Non-Small Cell Lung Cancer

Non-squamous Non-small Cell Lung Cancer
Hansoh BioMedical R&D Company1,080 enrolled2 locationsNCT06417008
Recruiting
Phase 3

A Study to Compare Effects and Safety of CT-P51 and Keytruda in Patients With Previously Untreated Metastatic Lung Cancer

Non-squamous Non-small Cell Lung Cancer
Celltrion606 enrolled1 locationNCT06939595
Recruiting
Phase 3

JAB-21822 Combined With JAB-3312 Compared SOC in the First Line for Treatment of Advanced Non-small Cell Lung Cancer With KRAS p.G12C Mutation

Advanced Non-squamous Non-small-cell Lung CancerMetastatic Non-Squamous Non-Small Cell Lung Cancer
Allist Pharmaceuticals, Inc.392 enrolled37 locationsNCT06416410
Recruiting
Phase 1

A Study of NI-1801 in Patients with Mesothelin Expressing Solid Cancers

Triple-Negative Breast CancerEndometrioid Ovarian CancerEpithelial Ovarian Cancer+2 more
Light Chain Bioscience - Novimmune SA70 enrolled7 locationsNCT05403554
Recruiting
Phase 2

Study of Crizotinib for ROS1 and MET Activated Lung Cancer

Stage IV Non-Small Cell Lung CancerMET AmplificationNon-squamous Non-small Cell Lung Cancer+2 more
University Health Network, Toronto50 enrolled1 locationNCT04084717
Recruiting
Phase 2

Anti-PD-1 Antibody Therapies of Camrelizumab in Combination With Pemetrexed and Carboplatin as First-line Treatment in Patients With Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer

Non-squamous Non-small Cell Lung Cancer
CrystalGenomics, Inc.60 enrolled8 locationsNCT05841472